From: FGFR1 amplification in breast carcinomas: a chromogenic in situhybridisation analysis
Parameter | Number of samples | Positive FGFR1 amplification number (%) | P value |
---|---|---|---|
Age | 478 | 0.027 | |
<50 years | 152 | 7 (4.6) | |
≥50 years | 346 | 35 (10.1) | |
Grade | 478 | Not significant | |
1 | 116 | 10 (8.6) | |
2 | 141 | 12 (8.5) | |
3 | 221 | 20 (9.0) | |
Size | 478 | Not significant | |
≥1.5 cm | 311 | 30 (9.6) | |
>1.5 cm | 167 | 12 (7.2) | |
Lymph node stage | 475 | Not significant | |
N0 | 322 | 28 (8.7) | |
N1 | 110 | 9 (8.2) | |
N2 | 43 | 4 (9.3) | |
Nottingham Prognostic Index | 475 | Not significant | |
Good | 175 | 14 (8.0) | |
Moderate | 239 | 21 (8.8) | |
Poor | 61 | 6 (9.8) | |
Distant metastasis | 478 | 0.050 | |
No | 394 | 30 (7.6) | |
Definite | 84 | 12 (14.3) | |
Vascular invasion | 467 | Not significant | |
No | 337 | 27 (8.0) | |
Yes | 130 | 14 (10.8) | |
Oestrogen receptor | 453 | Not significant | |
Negative | 140 | 10 (7.1) | |
Positive | 313 | 27 (8.6) | |
Progesterone receptor | 449 | 0.084 | |
Negative | 206 | 22 (10.7) | |
Positive | 243 | 15 (6.2) | |
HER2 | 445 | 0.043 | |
Negative | 259 | 28 (10.8) | |
Positive | 186 | 10 (5.4) | |
Androgen receptor | 415 | Not significant | |
Negative | 188 | 18 (9.6) | |
Positive | 227 | 13 (5.7) | |
Cytokeratin 7/8 | 467 | Not significant | |
Negative | 167 | 17 (10.2) | |
Positive | 300 | 24 (8.0) | |
Cytokeratin 18 | 396 | Not significant | |
Negative | 116 | 7 (6.0) | |
Positive | 280 | 23 (8.2) | |
Cytokeratin 19 | 464 | Not significant | |
Negative | 95 | 10 (10.5) | |
Positive | 369 | 30 (8.1) | |
Cytokeratin 5/6 | 465 | Not significant | |
Negative | 350 | 34 (9.7) | |
Positive | 115 | 6 (5.2) | |
Cytokeratin 14 | 458 | Not significant | |
Negative | 357 | 33 (9.2) | |
Positive | 101 | 6 (5.9) | |
Epidermal growth factor receptor | 351 | Not significant | |
Negative | 292 | 26 (8.9) | |
Positive | 59 | 3 (5.1) | |
Basal markers [27] | 455 | Not significant | |
Negative | 311 | 31 (10.0) | |
Positive | 144 | 8 (5.6) | |
Nielsen groups [28] | 396 | Not significant | |
HER2 | 39 | 3 (7.7) | |
Basal-like | 55 | 3 (5.5) | |
Luminal | 302 | 26 (8.6) |